Gilead Sciences: A ‘Slight Uplift’ for R&D Strategy?
September 26, 2016 at 10:46 AM EDT
Over the weekend, Gilead Science s ( GILD ) partner Galapagos ( GLPG ) announced positive results from a Phase II trial for a Crohn's disease treatment . Leerink's Geoffrey Porges and Bradley Canino consider the implications:
